Is Cronos Group (TSX:CRON) a Buy After its 1st-Quarter Performance?

Cronos Group remains a high-risk, high-reward stock, despite its solid first-quarter performance.

| More on:
edit Cannabis leaves of a plant on a dark background

Image source: Getty Images

Yesterday, Cronos Group (TSX:CRON)(NASDAQ:CRON) reported a solid first-quarter performance, with its top line outperforming analysts’ expectations by $1.24 million. Its net losses declined from $161.6 million in the previous year’s quarter to $32.7 million. Strong sales and a substantial decline in its net losses have increased investors’ confidence, increasing its stock price.

Yesterday, Cronos Group’s stock price rose to $4.38 before closing at $4.13, representing a 13.2% increase from its previous day’s closing price. Despite yesterday’s surge, the company is still trading over 17% lower for this year. So, will Cronos Group be an excellent buy at these levels amid its improving financials? Meanwhile, let us first look at its first-quarter performance in more detail.

Cronos Group’s first-quarter performance

Cronos Group’s first-quarter revenue came in at $25 million, representing a 99% growth from its previous year’s quarter. The growth in medical cannabis sales in Israel and the strengthening of its market share in the Canadian adult-use market drove its revenue. During the quarter, the company had increased its market share in the gummies and vapes categories.

Notably, Cronos Group’s gross margin also expanded from minus 23% to a positive 28% amid higher revenue from cannabis flows, the introduction of higher-margin cannabis extract products, and lower inventory valuation adjustments. The improvement in its gross margin and lower sales and marketing and R&D expenses led its net losses to contract by around 80%. The company also lowered its capital expenditures by $6.3 million to just $0.7 million. Meanwhile, its balance sheet looks solid, as its cash and cash equivalents stand at $1 billion at the end of the quarter.

After analyzing its first-quarter performance, let us access its growth prospects.

Growth prospects

Cronos Group is focusing on expanding its presence in Canada and Israel. In the Canadian recreational market, it expanded its product offering by launching new products in the gummies, vapes, and flower categories. It also plans to introduce Cosmic Green Apple and Polar Mint Vortex this month across several provinces, which could further strengthen its position in the vapes category. The company also focuses on enhancing its customer experience by developing blends of rare cannabinoids by breeding proprietary genetics.

In Israel, the company has witnessed a solid 40% growth in its volumes during the quarter. So, the company is focusing on bringing new innovative offerings to the country to boost its sales.

Further, its management has initiated a strategic plan to realign the business around its brands, centralize its functions under common leadership, and strengthen its supply chain. The company’s strategic realignment initiatives could deliver $20-$25 million in saving for this year, thus aiding the company in moving towards profitable and sustainable business. So, the company’s outlook looks healthy.

Bottom line

Despite a substantial improvement in its financials, Cronos Group remains a high-risk, high-reward stock, given the softness in the cannabis sector due to the delay in the federal approval for cannabis and its higher valuation. So, investors with a higher risk tolerance capacity can buy the stock.

Analysts favour a “hold” rating for the stock. Out of the 13 analysts covering Cronos Group, eight have issued a “hold” rating, while four analysts favor a “buy” rating, and the remaining one analyst has given a “sell” rating. Analysts’ consensus price target represents an upside potential of over 23%. 

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

The Motley Fool has no position in any of the stocks mentioned. Fool contributor Rajiv Nanjapla has no position in any of the stocks mentioned.

More on Cannabis Stocks

edit Jars of marijuana
Cannabis Stocks

Are Cannabis Stocks a Good Buy in March 2023?

Cannabis stocks like Canopy Growth Corp (TSX:WEED) are still being talked about, but are they worth buying?

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Down 26% in a Month, Is Canopy a Buy Today?

Canopy Growth Corp (TSX:WEED) is down 26% in a month. Is it time to start bottom fishing?

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

What’s Next for Aurora Cannabis Stock?

Aurora Cannabis stock is down 99% from all-time highs. Is ACB stock a buy, sell, or hold in March 2023?

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Canopy Growth Stock: Undervalued Gem or Falling Knife?

Canopy Growth remains a high-risk bet, despite falling 95% from all-time highs. Let's see why you need to avoid WEED…

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

3 Things to Know About Canopy Growth Stock After Earnings

A new focus on profitability and sustainability might stop the cash burn at Canopy Growth, so the stock can see…

Read more »

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »